Immunodeficiency in childhood

Current Allergy and Asthma Reports

Volumn 6, Issue 6, 2006, Pages 468-474

  Hernandez, Michelle ^a   Bastian, John F ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; AUTOANTIBODY; ENDONUCLEASE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN RECEPTOR; INTERLEUKIN RECEPTOR GAMMA CHAIN; PHOSPHOTRANSFERASE; PLASMID DNA; PROTEIN KINASE ZAP 70; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIVAGLOBULIN; ZINC FINGER PROTEIN;

ANTIBODY PRODUCTION; AREA UNDER THE CURVE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE CONTROL; DRUG BLOOD LEVEL; ENZYME DEFICIENCY; GENE THERAPY; HOMOLOGOUS RECOMBINATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; IPEX SYNDROME; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; MUTATIONAL ANALYSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC DISEASE; VIRAL GENE DELIVERY SYSTEM;

ANTIBODY FORMATION; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE THERAPY; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MALE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES, REGULATORY;

EID: 33750351764     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-006-0023-6     Document Type: Review

References (50)

1. Notarangelo L, Casanova JL, Conley ME, et al.: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006, 117:883-896.
2. Gatti RA, Meuwissen HJ, Allen HD, et al.: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 28:1366-1369.
3. Knight AK, Cunningham-Rundles C: Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmunol Rev 2006, 5:156-159.
4. Vorechovsky I, Cullen M, Carrington M, et al.: Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000, 164:4408-4416.
5. Grimbacher B, Warnatz K, Peter HH.: The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity. Curr Opin Allergy Clin Immunol 2003, 3:409-419.
6. Hutloff A, Dittrich AM, Beier KC, et al.: ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
7. Grimbacher B, Hutloff A, Schlesier M, et al.: Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003, 4:261-268.
8. Wu Y, Bressette D, Carrell JA, et al.: Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000, 275:35478-35485.
9. Seshasayee D, Valdez P, Yan M, et al.: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279-288.
10. Castigh E, Wilson SA, Garibyan L, et al.: TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005, 37: 829-834.
11. Salzer U, Chapel HM, Webster AD, et al.: Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005 37:820-828.
12. van Zelm MC, Reisli I, van der BM, et al.: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901-1912.
13. Farrington M, Grosmaire LS, Nonoyama S, et al.: CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A 1994 91:1099-1103.
14. Kanegane H, Tsukada S, Iwata T, et al.: Detection of Bruton's tyrosine kinase mutations in hypogam-maglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin Exp Immunol 2000, 120:512-517.
15. Morra M, Silander O, Calpe S, et al.: Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001, 98:1321-1325.
16. Spickett GP, Farrant J, North ME, et al.: Common variable immunodeficiency: How many diseases? Immunol Today 1997, 18:325-328.
17. Powell BR, Buist NR, Stenzel P: An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 1982, 100:731-737.
18. Chatila TA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005, 116:949-959.
19. Baud O, Goulet O, Canioni D, et al.: Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001, 344:1758-1762.
20. Lin W, Truong N, Grossman WJ, et al.: Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol 2005, 116:1106-1115.
21. Chatila TA, Blaeser F, Ho N, et al.: JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000, 106:R7S-R81.
22. Brunkow ME, Jeffery EW, Hjerrild KA, et al.: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
23. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD2S+ regulatory T cells. Nat Immunol 2003, 4:330-336.
24. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
25. Bettelli E, Dastrange M, Oukka M: Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 200S, 102:5138-5143.
26. Bennett CL, Brunkow ME, Ramsdell F, et al.: A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA←AAUGAA) leads to the IPEX syndrome. Immunogenetics 2001, 53:435-439.
27. Owen QJ, Jennings CE, Imrie H, et al.: Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. J Clin Endocrinol Metab 2003, 88:6034-6039.
28. Ku CL, Yang K, Bustamante J, et al.: Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005, 203:10-20.
29. Courtois G, Smahi A, Reichenbach J, et al.: A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003, 112:1108-1115.
30. Picard C, Puel A, Bonnet M, et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299:2076-2079.
31. Puel A, Yang K, Ku CL, et al.: Heritable defects of the human TLR signalling pathways. J Endotoxin Res 2005, 11:220-2204.
32. Puel A, Picard C, Ku CL, et al.: Inherited disorders of NF-kappaB-modiated immunity in man. Curr Opin Immunol 2004, 16:34-41.
33. Yang K, Puel A, Zhang S, et al.: Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005, 23:465-478.
34. Bruton OC: Agammaglobulinemia. Pediatrics 1952, 9:722-728.
35. Gardulf A, Hammarstrom. L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gamma-globulin by rapid infusion. Lancet 1991, 338:162-166.
36. Gardulf A, Andersen V, Bjorkander J, et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369.
37. Ochs HD, Gupta S, Kiessling P, et al.: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006, 26:265-273.
38. Chapel HM, Spickett GP, Ericson D, et al.: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94-100.
39. Gardulf A, Nicolay U, Asensio O, et al.: Rapid subcutaneous IgG replacement therapy is effective arid safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006, 26:177-185.
40. Kittner IM, Grimbacher B, Wulff W, et al.: Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006, 26:400-405.
41. Nicolay U, Kiessling P, Berger M, et al.: Health-related quality of life and treatment satisfaction in. North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006, 26:65-72.
42. Hershfield MS, Buckley RH, Greenberg ML, et al.: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987, 316:589-596.
43. Hacein-Bey-Abina S, le Deist F, Carlier F, et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185-1193.
44. Hacein-Bey-Abina S, Von KC, Schmidt M, et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
45. Woods NB, Bottero V, Schmidt M, et al.: Gene therapy: therapeutic gene causing lymphoma. Nature 2006, 440:1123.
46. Aiuti A, Slavin S, Aker M, et al.: Correction of ADA-SCID by stem cell gene therapy combined with nomnyeloablative conditioning. Science 2002, 296:2410-2413.
47. Ott MG, Schmidt M, Schwarzwaelder K, et al.: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006,12:401-409.
48. Sinn PL, Sauter SL, McCray PB Jr: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Tber 2005, 12:1089-1098.
49. Adjali O, Marodon G, Steinberg M, et al.: In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest 2005, 115:2287-2295.
50. Urnov FD, Miller JC, Lee YL, et al.: Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.